FGF21 and metabolic dysfunction-associated steatohepatitis: Notably, in another subgroup analysis, higher FGF-21 between patients with NAFLD and controls was observed within studies that included patients with NASH-related cirrhosis than those that did not include them (Table 4; Fig. S2j).